HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $214

Benzinga Newsdesk www.benzinga.com Positive 80.2%

Neg 0% Neu 0% Pos 80.2%

HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $200 to $214.